SS Innovations International Inc. has achieved a significant milestone by receiving regulatory approval from the Central Drugs Standard Control Organization (CDSCO), India's equivalent of the U.S. Food and Drug Administration, for both tele proctoring and telesurgery. This approval is pivotal for the company's advanced SSi Mantra surgical robotic technology platform, which includes cutting-edge telesurgery capabilities. The approval further enables SS Innovations to advance its mission of making robotic surgery affordable and accessible globally while addressing traditional obstacles related to travel, time, cost, and surgical accessibility.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.